Chemistry:Tolvaptan phosphate
From HandWiki
Short description: Drug for cardiac edema
 | |
| Clinical data | |
|---|---|
| Trade names | Samtasu |
| Other names | Tolvaptan sodium phosphate; OPC-61815 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C26H26ClN2O6P |
| Molar mass | 528.93 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tolvaptan phosphate is a drug used for the treatment of cardiac edema. It is a prodrug of tolvaptan,[1][2] formulated as the salt tolvaptan sodium phosphate, for intravenous administration. Tolvaptan phosphate is converted into the active drug tolvaptan in the human body following administration.
It was developed by Otsuka Pharmaceutical Co. and was approved for use in Japan in 2022.[3]
References
- ↑ "Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF) - A Phase III, Multicenter, Open-Label Trial". Circulation Journal 86 (7): 1068–1078. March 2022. doi:10.1253/circj.CJ-21-0926. PMID 35264514.
- ↑ "Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial". Circulation Journal 86 (4): 699–708. March 2022. doi:10.1253/circj.CJ-21-0430. PMID 34511586.
- ↑ "Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema" (Press release). Otsuka Pharmaceutical Co., Ltd. March 28, 2022. Retrieved June 11, 2022.
 |  |
